Fennec Pharmaceuticals Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Fennec Pharmaceuticals.

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Monday, March, 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.06.
View Fennec Pharmaceuticals' earnings history.

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FENC stock has decreased by 5.3% and is now trading at $6.28.
View which stocks have been most impacted by COVID-19.

3 brokers have issued twelve-month price objectives for Fennec Pharmaceuticals' shares. Their forecasts range from $11.00 to $18.00. On average, they expect Fennec Pharmaceuticals' share price to reach $14.67 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Fennec Pharmaceuticals include Vaxart (VXRT), DBV Technologies (DBVT), MeiraGTx (MGTX), Tarsus Pharmaceuticals (TARS), Compugen (CGEN), Agenus (AGEN), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Oyster Point Pharma (OYST), Precision BioSciences (DTIL), Freeline Therapeutics (FRLN), AVROBIO (AVRO), Aptose Biosciences (APTO), Gritstone Oncology (GRTS) and Jounce Therapeutics (JNCE).
View all of FENC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FENC stock can currently be purchased for approximately $6.28.

Fennec Pharmaceuticals has a market capitalization of $163.30 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.